Front. Cardiovasc. Med., 2022 June 13.
Interessenskonflikte: MB was supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TTR 219, project number 322900939), reports personal fees from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis, Servier, and Vifor, and participation in advisory boards for Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, Pfizer, ReCor, Servier, and Vifor, all outside the submitted work. FM was supported by Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Herzstiftung, Medtronic, and Recor Medical and has received scientific support and/or speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Merck, and ReCor Medical, all outside the submitted work. UL has received speaker honoraria from Amgen, Daiichi Sankyo, Novartis, and Sanofi. MS has received speaker honoraria from BMS, DGK-Academy, and Pfizer and consulting fees from MSD and Vifor, all outside the submitted work.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.